ATX
Director Trades
| Date | Director | Value |
|---|---|---|
| 19/12/24 | W. Tong | $80,000 |
| 19/12/24 | C. Burns | $40,000 |
| 19/12/24 | R. Peach | $125,000 |
| 19/12/24 | J. Bell | $80,000 |
Company News
Amplia Therapeutics Releases New Topline Data from ACCENT Narmafotinib Pancreatic Cancer Trial
Amplia Therapeutics (ASX: ATX) has released new topline data from an ongoing trial of its best-in-class selective FAK inhibitor narmafotinib on advanced pancreatic cancer. The ACCENT clinical trial is investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of narmafotinib when used in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Latest data to 20 July has […]
Amplia Therapeutics achieves second complete response with narmafotinib in pancreatic cancer trial
Amplia Therapeutics (ASX: ATX) continues to make excellent progress with focal adhesion kinase (FAK) inhibitor narmafotinib, its best-in-class drug candidate for pancreatic cancer. New data from the company’s ongoing ACCENT trial investigating narmafotinib has further confirmed its potential. After Amplia’s announcement earlier this week that a separate patient had achieved a pathological complete response (CR) […]
Amplia Therapeutics reports first pathological complete response in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX: ATX) has recorded the first pathological complete response (pCR) from a patient participating in the company’s ongoing ACCENT clinical trial to treat metastatic pancreatic cancer. The trial is investigating the company’s best-in-class FAK (focal adhesion kinase) inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. The patient recorded a pCR after […]
Amplia Therapeutics allocated FDA fast-tracking for pancreatic cancer drug narmafotinib
Melbourne-based Amplia Therapeutics (ASX: ATX) has been granted Fast Track Designation for its narmafotinib advanced pancreatic cancer treatment candidate by the US Food and Drug Administration (FDA). Narmafotinib is the company’s best-in-class inhibitor of the focal adhesion kinase protein (FAK), which is over-expressed in pancreatic and other cancers and a drug target gaining increasing attention […]
Amplia Therapeutics readies for phase 2 pancreatic cancer trial after lead drug manufactured
Amplia Therapeutics (ASX: ATX) is a step closer to phase 2 clinical trials in pancreatic cancer and lung fibrosis after completing a manufacturing run of its lead focal adhesion kinase (FAK) inhibitor drug AMP945. The company’s contractor has completed a 2 kilogram good manufacturing practice (GMP) run of AMP945 within budget and on time. Amplia […]
Amplia Therapeutics receives $2.1m grant to fast-track second cancer drug AMP886
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has been granted a $2.1 million government funding facility to accelerate work on its second focal adhesion kinase (FAK) inhibitor drug AMP886 for treating cancers and fibrotic disease. The company applied for the $2.1 million facility under the Victorian Government’s research and development cash flow loan initiative. It will […]
Amplia Therapeutics secures renowned oncology drug development expert as clinical advisor
Amplia Therapeutics (ASX: ATX) has appointed experienced spearhead of pancreatic cancer treatments Dr José Iglesias as clinical advisor to assist with development of its cancer and fibroid drugs. The company pointed out that Dr Iglesias was responsible for developing Abraxane, which is the cornerstone for the current standard of care in advanced pancreatic cancer. This […]
Amplia Therapeutics confirms anti-cancer drug AMP945 can inhibit focal adhesion kinase in healthy volunteers
Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has received new data from a recent phase 1 clinical trial, which demonstrates the ability of lead drug AMP945 to inhibit focal adhesion kinase (FAK) in healthy human volunteers when given as an oral capsule. Conducted at Nucleus Network in Melbourne, the trial aimed to establish the safety, […]
Amplia Therapeutics receives $1.14m tax refund for cancer drug development expenses
Clinical development company Amplia Therapeutics (ASX: ATX) has received a research and development tax incentive refund from the federal government for expenditure related to advancing its focal adhesion kinase (FAK) inhibitors for cancer and fibrotic diseases. The company received $1.14 million to cover expenses incurred during the 2020/2021 financial year in the development of its highly-potent and […]
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer
New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prior to administering standard chemotherapy. Published by Garvan Institute of Medical Research, the study was led by Professor Paul Timpson who works […]
